細胞材料開発室　-CELL BANK-

1）新型コロナウイルス感染症に対する理研BRCの取り組み

理研バイオリソース研究センター(理研BRC)は、遺伝子/細胞/マウス個体の三つの生命階層のリソースを1機関で取り揃えた、世界的にもユニークなリソース機関です。この特徴を活かして、新型コロナウイルス感染症の統合的な研究の促進のため、感染症の4つのステージ（①ウイルス感染・増殖、②発症・生体防御、③重症化、④治療・予防）の研究開発の鍵となるバイオリソースを収集・整備し、情報発信していきます。

COVID-19 関連マウスリソース(実験動物開発室）

SARS-CoV-2 relevant human genes(遺伝子材料開発室）

---

2）COVID-19 関連寄託細胞株 提供を開始しました。

Reference	BRC Resource	特性
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection	RCB5391 R52_Spike	抗SARS-CoV-2 Spike抗体(Clone R52)を産生するハイブリドーマ。
	RCB5392 S1D7_Spike	抗SARS-CoV-2 Spike抗体(Clone S1D7)を産生するハイブリドーマ。
	RCB5393 S3D8_Spike	抗SARS-CoV-2 Spike抗体(Clone S3D8)を産生するハイブリドーマ。

---

3）BRCから提供した細胞を利用した COVID-19 関連文献

	BRC Resource	Journal	Reference
1	RCB2202 293T	Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14	Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry
2	RCB0007 HeLa	Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751	Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor
3	RCB0995 MDCK	Clin Infect Dis. 2020 Oct 3;ciaa1517	Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19
4	RCB0535 RAW 264	Viruses. 2020 Jun 28;12(7):699	Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2
5	RCB0988 CACO-2 CSII-CMV-MCS-IRES2-Bsd	PLoS Pathog. 2021 Jan 21;17(1):e1009233.	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
6	RCB0485 LA-N-5	Sci Rep. 2021 Feb 9;11(1):3379	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
7	RCB2202 293T	Cell. 2021 Jun 24;184(13):3452-3466.e18	An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
8	RCB1902 HSC-4	J Anat. 2021 Jun;238(6):1341-1354	Expression of SARS‐CoV‐2 entry factors in human oral tissue
9	RCB0209 SP2/0-Ag14	J Biol Chem. Jan-Jun 2021;296:100346	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
10	RCB0988 CACO-2 RCB2202 293T	Sci Rep. 2021 Mar 8;11(1):5376	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
11	RCB0988 CACO-2	J Virol. 2022 Mar 23;96(6):e0000222 (bioRxiv. June 30, 2021)	Host cellular RNA helicases regulate SARS-CoV-2 infection
12	RCB0211 MRC-5	Cell Rep Med. 2021 Jun 15;2(6):100311	Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
13	RCB2202 293T	bioRxiv. August 23, 2021	The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
14	RCB0098 A549	Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151	Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells
15	HPS0002 253G1	J Toxicol Sci. 2021; 46(9):425-435	Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing
16	RCB0098 A549 RCB0988 CACO-2 RCB1942 HuH-7	iScience. 2021 Oct 22;24(10):103120	5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2
17	RCB0771 XTC-YF	Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):477-484	Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile
18	RCB1168 SKW-3	Commun Biol. 2021 Dec 2;4(1):1365	Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
19	RCB0001 Vero	iScience. 2021 Nov 17;103379	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
20	RCB0098 A549 RCB0988 CACO-2 HuH-7	Nat Commun. 2021 Nov 15;12(1):6602	SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis
21	RCB4557 HUDEP-2	Nat Genet. 2021 Nov;53(11):1606-1615	Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
22	RCB0995 MDCK	J Infect Chemother. 2022 Feb;28(2):252-256.	Stability of SARS-CoV-2 and influenza virus varies across different paper types
23	RCB0988 CAC0-2	Experimental and Therapeutic Medicine 2022-2-10	Indigo plant leaf extract inhibits the binding of SARS‑CoV‑2 spike protein to angiotensin‑converting enzyme 2
24	NIH3T3	Cancer Sci. 2022 Aug;113(8):2536-2547	A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer
25	RCB2202 293T	J Med Chem. 2022 Oct 27;65(20):13852-13865	Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
26	RCB2202 293T RCB0001 Vero	Pharm Res. 2022 Sep 26;1-9	Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
27	RCB1637 293	Commun Biol. 2022 Nov 5;5(1):1188	ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner
28	RCB2630 B16F10	Cell. 2022 Jun 9;185(12):2103-2115.e19	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
29	RCB0098 A549 RCB2202 293T	J Biol Chem. 2022 Nov;298(11):102500	Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis
30	RCB0995 MDCK RCB2202 293T	J Nat Prod. 2022 Nov 25;85(11):2583-2591	Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses
31	RC2202 293T	Sci Transl Med. 2023 Jan 18;15(679):eabq4064	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
32	RC2202 293T RCB0001 Vero	iScience. 2023 Jan 20;26(1):105742	Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists

---

4）COVID-19 研究のための細胞株

	BRC Cell Line	Cell Line	Reference
1	Vero E6, RCB0001 Vero RCB0988 CACO-2 Calu-3 RCB2202 293T RCB1366 HuH-7	Vero E6 Caco-2 Calu-3 HEK293T Huh7	In Vitro and Animal Models for SARS-CoV-2 research
2	Vero E6 RCB0001 Vero RCB1366 HuH-7 RCB2202 293T RCB0098 A549, RCB3677 A549 EFKB3	Vero E6 Vero HUH 7.0 293T A549 EFKB3	Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
3	RCB0001 Vero RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1366 HuH-7	Vero HeLa HEK293T/F Huh7	A Thermostable mRNA Vaccine against COVID-19
4	RCB1637 293 RCB2202 293T RCB0098 A549, RCB3677 A549 RCB0218 MRC-5, known PDL Vero E6, RCB0001 Vero Vero 81 RCB0007 HeLa, RCB3680 HeLa RCB1366 HuH-7	293 293T A549 MRC5 Vero E6 Vero 81 HeLa Huh7	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
5	RCB1648 Hep G2 RCB1366 HuH-7 RCB2202 293T RCB0001 Vero CHO RCB0995 MDCK	HepG2 Huh-7 293T Vero CHO MDCK	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
6	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
7	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
8	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
9	Vero E6, RCB0001 Vero RCB1366 HuH-7	Vero E6 Huh-7	A pneumonia outbreak associated with a new coronavirus of probable bat origin
10	RCB1637 293 RCB1366 HuH-7 RCB1423 BHK-21 Vero E6, RCB0001 Vero	HEK293 Huh-7 BHK21 Vero-E6	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε
11	RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1423 BHK-21 RCB0988 CACO-2	HeLa 293T BHK-21 Caco-2	COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
12	RCB0988 CACO-2	Caco-2	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
13	RCB0988 CACO-2	Caco-2	A metabolic handbook for the COVID-19 pandemic
14	RCB2202 293T RCB0098 A549, RCB3677 A549 BHK RCB0988 CACO-2 RCB1366 HuH-7 PK-15	293T A549 BHK Caco-2 Huh-7.5 PK-15	Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
15	RCB2202 293T RCB0098 A549, RCB3677 A549	HEK293T A549	Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
16	RCB2202 293T RCB0007 HeLa, RCB3680 HeLa Calu-3 RCB0218 MRC-5, known PDL	HEK293T HeLa Calu-3 MRC-5	Cell entry mechanisms of SARS-CoV-2
17	RCB2202 293T HEK293F RCB0007 HeLa, RCB3680 HeLa RCB0218 MRC-5, known PDL	HEK293T HEK293F HeLa MRC5	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
18	RCB1366 HuH-7 Huh-7.5	Huh-7 Huh-7.5	Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
19	RCB0994 MA104 RCB1637 293	MA104 HEK293	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
20	RCB0218 MRC-5, known PDL	MRC-5	Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
21	Fcwf-4 A72 RCB0995 MDCK DH82	Fcwf-4 A72 MDCK DH82	Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663
22	GES-1 RCB1189 THP-1,RCB3686 THP-1	GES-1 THP-1	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels